Shanghai YingLi Pharmaceutical Co. Ltd.: Neoplasms trials

The registry lists 11 Neoplasms studies with Shanghai YingLi Pharmaceutical Co. Ltd. as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 11Phase 2 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of AK-1286 in Patients With Advanced Solid TumorsNot yet recruitingNCT06779045Phase 1
• Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRASRecruitingNCT06096974Phase 1
• A Study of YL-17231 in Patients With Advanced Solid TumorsRecruitingNCT06078800Phase 1
• A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid TumorNot yet recruitingNCT06026501Phase 1/2
• A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid TumorsStatus unknownNCT05457517Phase 1/2
• A Study of Linperlisib Combination With Camrelizumab in Patients With Solid TumorStatus unknownNCT05429398Phase 1
• YL-13027 in Patients With Advanced Solid TumorsStatus unknownNCT05228600Phase 1
• Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS MutationStatus unknownNCT05173805Phase 1/2
• A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C MutationStatus unknownNCT05119933Phase 1/2
• A Phase I Study of YY-20394 in Patients With Advanced Solid TumorsStatus unknownNCT04049929Phase 1
• First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid TumorsStatus unknownNCT03869632Phase 1